Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02655822 · ClinicalTrials.gov registry record · Phase 1
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
A Phase 1 study, sponsored by Corvus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 502
- Enrollment target
NCT02655822: Completed Phase 1 study, sponsored by Corvus Pharmaceuticals.
NCT02655822 is a Phase 1 study that has completed, run by Corvus Pharmaceuticals. The registered enrollment target is 502 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (737% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02655822, a Phase 1 study, has completed, sponsored by Corvus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 502 participants
- Enrollment target
Study Summary
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.
Interventions
- DRUG Ciforadenant
- DRUG Ciforadenant + atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 502 participants |
| Start Date | 2016-01 |
| Est. Completion | 2021-07 |
| Phase | Phase 1 |
What the finished NCT02655822 record still lists
NCT02655822 is an interventional study that assigns participants to a tested intervention. The registered 502 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (737% higher).
The record links to 0 conditions, and to 2 interventions - of which Ciforadenant is the first listed.
NCT02655822 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02655822 about?
NCT02655822 is a clinical study titled "Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers". This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single a...
What is the current status of trial NCT02655822?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 502 participants. The study started on 2016-01. Estimated completion is 2021-07.
What interventions are being tested in trial NCT02655822?
The interventions under investigation include: Ciforadenant (DRUG), Ciforadenant + atezolizumab (DRUG).
Who is sponsoring clinical trial NCT02655822?
This trial is sponsored by Corvus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02655822's enrollment target sits among peer trials
502 44th of 2000 higher than 1,957 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
- NCT05143931 · 503 participants · NA
Avoid and Resist Strategies for Weight Management
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia